Elephas Biosciences announced today that its first cancer patient was screened at inDNA Life Sciences in India, as part of a study that aims to demonstrate that the Elphas Live Platform can accurately predict immunotherapy response in the Indian cancer patient population.

“This is a critical milestone as we demonstrate how our technology can predict which patients will respond to existing immunotherapy treatments,” Elephas Founder and CEO Maneesh K. Arora said in a statement. “We are grateful to have a strategic partnership with Dr. Birendranath Banerjee and inDNA, whose team has welcomed us with the spirit of collaboration and a similar passion for improving cancer outcomes.”

As previously reported, the clinical tissue samples will be collected from patients who are likely to receive immunotherapy based on their cancer diagnosis, allowing the Elephas Live Platform to best evaluate and predict how each patient will respond to treatment.

This is the first international deployment of the Elephas Live Platform.